Kintor Pharmaceutical Limited, a clinical-stage biotechnology company, engages in researching, developing, and commercializing therapeutic drugs for dermatology and tumors indications with the unmet medical needs in the People's Republic of China. Its product candidates include KX-826, a potential topical drug for the treatment of androgenic alopecia and acne vulgaris; and Pruxelutamide (GT0918), a second-generation androgen receptor (AR) for the treatment of metastatic castration-resistant prostate cancer, COVID-19, and AR+ metastatic breast cancer, as well as AR-PROTAC Compound (GT20029). The company is developing Pruxelutamide (GT0918), a second generation androgen receptor (AR) for the metastatic castration-resistant prostate cancer, COVID-19, and AR+ metastatic breast cancer; GT1708F (Hedgehog/SMO Inhibitor), an inhibitor of the hedgehog signal transduction pathway to treat idiopathic pulmonary fibrosis, and blood cancer; GT0486, an inhibitor of the PI3K/mTOR signalling pathway and a second generation mTOR inhibitor for the treatment of metastatic solid tumours, such as breast cancer, prostate cancer, and hepatocellular carcinoma (HCC); and ALK-1 Antibody (GT90001), an anti-angiogenesis inhibitor and targets a new biological target activin receptor-like kinase-1 globally to treat metastatic hepatocellular carcinoma, a common type of liver cancer, and a variety of solid tumours. Kintor Pharmaceutical Limited was founded in 2009 and is headquartered in Suzhou, the People's Republic of China. Address: Suzhou Industrial Park, Suzhou, China, 215123